-
Session will explore crossover benefits of heart, kidney treatments
“Diabetes-dedicated professionals can be very successful at managing diabetes, but they want to be equally successful in reducing the risks of heart failure hospitalizations, myocardial infarctions, stroke, and cardiovascular death. They want to be equally successful in reducing the progression of kidney disease and reducing the chances of patients ending up on dialysis, or at…
-
Experts will debate recommendations for blood pressure targets, metformin use
Should the blood pressure target for all individuals with type 2 diabetes and hypertension be
-
Make plans to attend virtual Corporate Symposia during the Scientific Sessions
Corporate Symposia are programs that are planned and conducted by the corporate community in conjunction with the Virtual 80th Scientific Sessions to provide attendees with additional educational opportunities. There are currently 10 Corporate Symposia scheduled beginning Friday, June 12.
-
Sympathetic-Associated Macrophages in Energy Homeostasis
Ana Domingos, PhD, previews her presentation “Sympathetic-Associated Macrophages in Energy Homeostasis,” which begins at 5:00 p.m. CT Saturday, June 13.
-
DAPA-HF Update—Have We Lost SGLT2 Inhibitors to Cardiologists?! Background and Main Cardiovascular Outcomes
John JV McMurray, OBE, BSc (Hons), MB, ChB (Hons), MD, Professor of Medical Cardiology, University of Glasgow, previews his presentation “DAPA-HF Update—Have We Lost SGLT2 Inhibitors to Cardiologists?! Background and Main Cardiovascular Outcomes,” which begins at 4:00 p.m. CT Saturday, June 13.
-
Efficacy of Personalized Nutrition Based on Gut Microbiome and Clinical Data in Prediabetes
Eran Segal, PhD, previews his presentation “Efficacy of Personalized Nutrition Based on Gut Microbiome and Clinical Data in Prediabetes,” which begins at 11:40 a.m. CT Saturday, June 13.
-
Professional Interest Group Discussion on Nutritional Science and Metabolism—Emerging Methodologies for Personalized Nutrition—Potential Effects on Glycemic and Other Diabetes-Related Outcomes?
Guoxun Chen, PhD, previews his response and discussion from the Professional Interest Group Discussion “Nutritional Science and Metabolism—Emerging Methodologies for Personalized Nutrition—Potential Effects on Glycemic and Other Diabetes-Related Outcomes?” The session begins at 11:30 a.m. CT Saturday, June 13. Dr. Chen’s presentation will begin at 12:10 p.m. CT.
-
The Bexagliflozin Efficacy and Safety Trial (BEST): A Randomized, Double-Blind, Placebo-Controlled, Phase IIII, Clinical Trial
John JV McMurray, OBE, BSc (Hons), MB, ChB (Hons), MD, Professor of Medical Cardiology, University of Glasgow, previews his presentation “The Bexagliflozin Efficacy and Safety Trial (BEST): A Randomized, Double-Blind, Placebo-Controlled, Phase IIII, Clinical Trial,” which begins at 6 p.m. CT Friday, June 12.
-
Oral Agents for Gestational Diabetes Mellitus—Are We Stuck Using Insulin?
Linda A. Barbour, MD, MSPH, FACP, Professor of Endocrinology and Maternal-Fetal Medicine, University of Colorado Anschutz Medical Campus, previews her presentation “Oral Agents for Gestational Diabetes Mellitus—Are We Stuck Using Insulin?” which begins at 1:15 p.m. CT Friday, June 12.
-
AI for Risk Assessment and Blood Glucose Control
Josep Vehí, PhD, previews his presentation “AI for Risk Assessment and Blood Glucose Control,” which begins at 2:15 p.m. CT Monday, June 15.